Physician profile
Tara Frederick
NPI 1497417265
$554.94
in general payments reported to CMS, 2019-2025
20 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.28 · 2023: $95.88 · 2024: $82.73 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73.88 | 2025 | |
| Janssen Pharmaceuticals, INC | $64.47 | 2024-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $45.09 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $37.48 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Organon LLC | $33.54 | 2023 | Nexplanon |
| Astellas Pharma US INC | $32.04 | 2023-2025 | Veozah, Myrbetriq |
| Indivior INC. | $31.65 | 2024-2025 | Sublocade |
| Alkermes, INC. | $27.43 | 2025 | Vivitrol |
| Boston Scientific Corporation | $22.49 | 2025 | Cds - Mct/Cem Monitoring |
| Neurocrine Biosciences, INC. | $19.62 | 2025 | |
| Axsome Therapeutics, INC. | $19.45 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $18.94 | 2025 | Austedo Xr |
| Pfizer INC. | $16.90 | 2025 | |
| Lilly USA, LLC | $16.71 | 2025 | Mounjaro, Zepbound |
| Agile Therapeutics, INC. | $16.47 | 2023 | Twirla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.09 | 2024 | Pediarix, Bexsero, Rotarix |
| Merck Sharp & Dohme LLC | $15.93 | 2024 | Gardasil, Gardasil 9 |
| Exeltis, USA INC. | $15.83 | 2023 | Slynd |
| Novo Nordisk INC | $15.76 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.